Since their discovery almost two decades ago, interleukin-17-producing CD4+ T cells (TH17
cells) have been implicated in the pathogenesis of multiple autoimmune and inflammatory …

Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …

Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide,
presenting at any age, and leading to a substantial burden for individuals and society. It is …

Background The use of monoclonal antibodies has changed the treatment of several
immune-mediated inflammatory diseases, including psoriasis. However, these large …

Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …

Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by
the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is …

Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation …

Innate immunity represents the semi-specific first line of defense and provides the initial host
response to tissue injury, trauma, and pathogens. Innate immunity activates the adaptive …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …